Brief: Clarity Pharma Updates On Phase III Trial Of 64 Cu Sar-Bispsma Diagnostic In Prostate Cancer
04/07/2023 02:25
July 4 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* COMMENCING PHASE III TRIAL OF ITS 64 CU SAR-BISPSMA
DIAGNOSTIC
IN PROSTATE CANCER
* TRIAL EXPECTED TO COMMENCE IN LATE 2023
Source text for Eikon: ID:nASX9WcCWN
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial